Total cost and cost predictors in systemic lupus erythematosus - 8-years follow-up of a Swedish inception cohort

Lupus

Volumn 24, Issue 12, 2015, Pages 1248-1256

  Jonsen A ^a   Bengtsson, A A ^a   Hjalte, F ^b   Petersson, I F ^a   Willim, M ^a   Nived, O ^a  

^a LUND UNIVERSITY   (Sweden)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

health economics; inception cohort; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; ILOPROST; IMMUNOGLOBULIN; IMMUNOLOGIC AGENT; METAMOL; METHOTREXATE; MYCOPHENOLATE MOFETIL; PRESCRIPTION DRUG; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE REGISTRY; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OUTPATIENT; PHARMACEUTICAL CARE; PREDICTOR VARIABLE; PRESCRIPTION; PRIORITY JOURNAL; RESIDENTIAL AREA; SEX RATIO; SOCIAL INSURANCE; SWEDEN; SYSTEMIC LUPUS ERYTHEMATOSUS; ARTHRITIS; CAUCASIAN; CHILD; COMPLICATION; COST OF ILLNESS; ECONOMICS; MIDDLE AGED; NEPHRITIS; SKIN DISEASE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS; CHILD; COST OF ILLNESS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; NEPHRITIS; SKIN DISEASES; SWEDEN; YOUNG ADULT;

EID: 84938912811     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203315584812     Document Type: Article

References (37)

1. Gladman DD, Urowitz MB, Rahman P, Ibanez D, Tam LS,. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003; 30: 1955-1959.
2. Ståhl Hallengren C, Jönsen A, Nived O, Sturfelt G,. Incidence studies of systemic lupus erythematosus in southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 2000; 27: 685-691.
3. Zhu TY, Tam LS, Li EK,. Cost-of-illness studies in systemic lupus erythematosus: a systematic review. Arthritis Care Res 2011; 63: 751-760.
4. Kortt MA, Langley PC, Cox ER,. A review of cost-of-illness studies on obesity. Clin Ther 1998; 20: 772-779.
5. Drummond FM, Schulper J.M, Torrance WG, O 'Brien JB, Stoddart LG. Methods for the economic evaluation of health care programmes. Oxford University Press, 2005.
6. Johannesson M. Theory and methods of economic evaluation of health care. Kluwer Academic Publishers, 1996.
7. Kobelt G,. Health economics: an introduction to economic evaluation, London: Office of Health Economics, 2002.
8. Carls G, Li T, Panopalis P, Wang S, et al. Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis. J Occup Environ Med 2009; 51: 66-79.
9. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ,. Long term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five year analysis of a large Medicaid population. Arthritis Rheum 2009; 61: 755-763.
10. Panopalis P, Yazdany J, Gillis JZ, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum 2008; 59: 1788-1795.
11. Pelletier EM, Ogale S, Yu E, Brunetta P, Garg J,. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database. Clin Ther 2009; 31: 2653-2664.
12. Pons Estel GJ, Alarcón GS, Scofield L, Reunlib L, Cooper GS,. Understanding the epidemiology and progression of systemic lupus erythematosus. Sem Arthritis Rheum 2010; 39: 257-268.
13. Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, Goss TF,. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res 2011; 63: 1224-1232.
14. Turchetti G, Yazdany J, Palia I, Yelin E, Mosca M,. Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider. Clin Exp Rheumatol 2012; 30 (4 Suppl 73): 116-122.
15. Panopalis P, Clarke AE, Yelin E,. The economic burden of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2012; 26: 695-704.
16. Fries JF, Holman HR,. Systemic lupus erythematosus: a clinical analysis. Major Probl Intern Med 1975; 6: v-v.
17. Nived O, Sturfelt G, Wollheim F,. Systemic lupus erythematosus in an adult population in southern Sweden. Incidence, prevalence and validity of ARA revised classification criteria. Br J Rheum 1985; 24: 147-154.
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383.
19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
20. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809-813.
21. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH,. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
22. Gladman DD, Ibanez D, Urowitz MB,. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288-291.
23. Statistics Sweden (SCB). Lönestatistik, (2011) www.scb.se (2011, accessed 14 June 2012).
24. Ekonomifakta. (2011). Sociala avgifter 2011, www.ekonomifakta.se (2011, accessed 14 June 2012).
25. Nived O, Andersson M, Lindgren M, et al. Adherence to advice and prescriptions in SLE is mostly good, but better follow up is needed: a study with a questionnaire. Lupus 2007; 16: 701-706.
26. Clarke AE, Petri M, Manzi S, et al. The systemic lupus erythematosus Tri-nation Study: absence of a link between health resource use and health outcome. Rheumatology 2004; 43: 1016-1024.
27. Zhu TY, Tam LS, Lee VW, Lee KK, Li EK,. The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1159-1167.
28. Sutcliffe N, Clarke AE, Taylor R, Frost C, Isenberg DA,. Total cost and predictors of costs in patients with systemic lupus erythematosus. Rheumatology 2001; 40: 37-47.
29. Doria A, Amoura Z, Cervera R, et al. Annual direct medical cost of active systemic lupus erythematosus in five European countries. Ann Rheum Dis 2014; 73: 154-160.
30. Clarke AE, Panopalis P, Petri M, et al. SLE patients with renal damage incur high health care costs. Rheumatology 2008; 47: 329-333.
31. Agdassi E, Zhang W, St-Pierre Y, et al. Healthcare costs and loss of productivity in a Canadian population of patients with and without lupus nephritis. J Rheumatol 2011; 38: 658-666.
32. Panopalis P, Petri M, Manzi S, et al. The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. Arthritis Rheum 2007; 57: 64-70.
33. Baker K, Pope J,. Employment and work disability in systemic lupus erythematosus: a systematic review. Rheumatology 2009; 48: 281-284.
34. Yelin E, Trupin L, Katz P, et al. Work dynamics among persons with systemic lupus erythematosus. Arthritis Rheum 2007; 57: 56-63.
35. Campbell R Jr, Cooper GS, Gilkeson GS,. The impact of systemic lupus erythematosus on employment. J Rheumatol 2009; 36: 2470-2475.
36. Yelin E, Tonner C, Trupin L, et al. Work loss and work entry among persons with systemic lupus erythematosus: comparisons with a national matched sample. Arthritis Rheum 2009; 61: 247-258.
37. Clarke AE, Penrod J, St Pierre Y, et al. Underestimating the value of women: assessing the indirect costs of women with systemic lupus erythematosus. J Rheumatol 2000; 27: 2597-2604.